Evidence map›Paper›PMID 31397880›Full record

SynthesisClinical genetics2019

MAGEL2-related disorders: A study and case series.

Jameson Patak, James Gilfert, Melissa Byler, Vamsee Neerukonda, Isabelle Thiffault, Laura Cross, Shivarajan Amudhavalli, Marta Pacio-Miguez, Maria Palomares-Bralo, Sixto Garcia-Minaur and 10 more

Abstract readCase ReportsSystematic Review
In one paragraph

Synthesis in Clinical genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. MAGEL2 (patho-)physiology and Schaaf-Yang syndrome.Developmental medicine and child neurology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. [Recent advances in the genetic etiology of central precocious puberty].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024
    Review
  10. Article
  11. Article
  12. AAV-BDNF gene therapy ameliorates a hypothalamic neuroinflammatory signature in theMolecular therapy. Methods & clinical development · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Leptin signaling and leptin resistance.Medical review (2021) · 2022
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Jameson PatakDivision of Development, Behavior and Genetics, SUNY Upstate Medical University, Syracuse, New York.ORCID 0000-0002-8567-4041
James GilfertDivision of Development, Behavior and Genetics, SUNY Upstate Medical University, Syracuse, New York.
Melissa BylerDivision of Development, Behavior and Genetics, SUNY Upstate Medical University, Syracuse, New York.
Vamsee NeerukondaDivision of Development, Behavior and Genetics, SUNY Upstate Medical University, Syracuse, New York.
Isabelle ThiffaultCenter for Pediatric Genomic Medicine, Children's Mercy Kansas City, Kansas City, Missouri.ORCID 0000-0001-7987-6731
Laura CrossDepartment of Pathology & Genetics, Children's Mercy Hospitals, Kansas City, Missouri.
Shivarajan AmudhavalliDepartment of Pathology & Genetics, Children's Mercy Hospitals, Kansas City, Missouri.
Marta Pacio-MiguezInstituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, IdiPaz, Madrid, Spain.
Maria Palomares-BraloInstituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, IdiPaz, Madrid, Spain.
Sixto Garcia-MinaurInstituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, IdiPaz, Madrid, Spain.
Fernando Santos-SimarroInstituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, IdiPaz, Madrid, Spain.
Zoe PowisAmbry Genetics Corporation, Aliso Viejo, California.ORCID 0000-0002-1347-4358
Wendy AlcarazAmbry Genetics Corporation, Aliso Viejo, California.
Sha TangAmbry Genetics Corporation, Aliso Viejo, California.
Julie JurgensDepartment of Neurology, Boston Children's Hospital, Boston, Massachusetts.
Brenda BarryDepartment of Neurology, Boston Children's Hospital, Boston, Massachusetts.
Eleina EnglandCenter for Mendelian Genomics and Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Elizabeth EngleDepartment of Neurology, Boston Children's Hospital, Boston, Massachusetts.
Jonathon HessDepartment of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York.
Robert R LebelDivision of Development, Behavior and Genetics, SUNY Upstate Medical University, Syracuse, New York.
SUNY Upstate Medical University · USHospital Universitario La Paz · ESAmbry Genetics (United States) · USBoston Children's Hospital · USChildren's Mercy Hospital · USBroad Institute · US

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Joint Center for Mendelian GenomicsUM1HG008900 · NHGRI · BROAD INSTITUTE, INC. · PI O'DONNELL-LURIA, ANNE, REHM, HEIDI L · 2016 to 2020
$16.5M
Baylor-Johns Hopkins Center for Mendelian GeneticsUM1HG006542 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 2016 to 2020
$14.5M
Predoctoral Training Program in Human GeneticsT32GM007814 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 1985 to 2021
$10.6M
Steps towards a paternal gene activation therapy for Angelman syndromeU54HD083092 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI NELSON, DAVID LOREN, SAMACO, RODNEY C · 2014 to 2019
$7.8M
Training Program in the Molecular Bases of Eye DiseasesT32EY007145 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore, MEREDITH GREGORY-KSANDER · 1997 to 2026
$4.5M
Dissecting ocular congenital cranial dysinnervation disorders through whole genome sequence analysisR01EY027421 · NEI · BOSTON CHILDREN'S HOSPITAL · PI ENGLE, ELIZABETH C. · 2017 to 2021
$3.1M
Howard Hughes Medical InstituteNEI NIH HHS P30 EY003790NEI NIH HHS R01 EY027421NEI NIH HHS T32 EY007145NHGRI NIH HHS UM1 HG006542NHGRI NIH HHS UM1 HG008900NICHD NIH HHS U54 HD083092NIGMS NIH HHS T32 GM007814
6 · The paper itself

Abstract

Pathogenic MAGEL2 variants result in the phenotypes of Chitayat-Hall syndrome (CHS), Schaaf-Yang syndrome (SYS) and Prader-Willi syndrome (PWS). We present five patients with mutations in MAGEL2, including the first patient reported with a missense variant, adding to the limited literature. Further, we performed a systematic review of the CHS and SYS literature, assess the overlap between CHS, SYS and PWS, and analyze genotype-phenotype correlations among them. We conclude that there is neither a clinical nor etiological difference between CHS and SYS, and propose that the two syndromes simply be referred to as MAGEL2-related disorders.

Indexed as

Abnormalities, MultipleAdultChild, PreschoolCluster AnalysisDNA Mutational AnalysisFemaleHumansInfantInfant, NewbornIntracellular Signaling Peptides and ProteinsIntrinsically Disordered ProteinsMaleMutationProteinsYoung AdultIntracellular Signaling Peptides and ProteinsIntrinsically Disordered ProteinsMAGEL2 protein, humanProteinsChitayat-Hall syndromeMAGEL2MAGEL2-related disorderPrader-Willi syndrome locusSchaaf-Yang syndrome

Identifiers

PMID31397880
PMCPMC6864226
OpenAlexW2968210574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.